{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:08:52Z","timestamp":1788790132185,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Juvenile idiopathic arthritis-associated uveitis (JIA-U) is a common and sight-threatening extra-articular manifestation of juvenile idiopathic arthritis, typically presenting as chronic noninfectious anterior uveitis. Its early symptoms are often insidious, and delayed detection and treatment may lead to cataract, glaucoma, macular edema, and irreversible visual impairment. Conventional treatment is based on glucocorticoids and immunosuppressants; however, some children continue to experience inadequate efficacy, glucocorticoid dependence, drug intolerance, or adverse events. In recent years, substantial progress has been made in the use of biologics for JIA-U. Among them, tumor necrosis factor-\u03b1 inhibitors, particularly adalimumab, have shown potential for controlling ocular inflammation, reducing glucocorticoid exposure, and improving visual outcomes, thereby offering a new therapeutic avenue for patients with JIA-U. Although TNF-\u03b1 inhibitors have become an important component of systemic therapy for JIA-U, optimal dosing, long-term maintenance, tapering, and the timing of discontinuation require further investigation. Additional prospective, disease-specific pediatric studies are needed to define the optimal timing of TNF-\u03b1 inhibitor initiation, precise dose-adjustment strategies, and long-term safety management, thereby advancing individualized and precision treatment for JIA-U.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1966054","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:13:40Z","timestamp":1788786820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in tumor necrosis factor-\u03b1 inhibitors for the treatment of juvenile idiopathic arthritis-associated uveitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hanbing","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2231154","article-title":"Juvenile idiopathic arthritis and its associated uveitis","volume":"19","author":"Maleki","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5152\/TurkArchPediatr.2023.23086","article-title":"An overview of pediatric uveitis","volume":"58","author":"Tu\u011fal-Tutkun","year":"2023","journal-title":"Turk Arch Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2024.2305567","article-title":"A clearer vision: insights into juvenile idiopathic arthritis\u2013associated uveitis","volume":"37","author":"Bani Khalaf","year":"2024","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24963","article-title":"New and updated recommendations for the treatment of juvenile idiopathic arthritis\u2013associated uveitis and idiopathic chronic anterior uveitis","volume":"75","author":"Foeldvari","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23871","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis\u2013associated uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00296-x","article-title":"Efficacy and safety of anti-TNF\u03b1 therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Rheumatol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key406","article-title":"Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) study","volume":"58","author":"Heiligenhaus","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2024.1412930","article-title":"Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond","volume":"4","author":"Chauhan","year":"2024","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti\u2013tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.2147\/DDDT.S94188","article-title":"Profile of adalimumab and its potential in the treatment of uveitis","volume":"10","author":"Rabinovich","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41584-024-01181-x","article-title":"The management of adult and paediatric uveitis for rheumatologists","volume":"20","author":"Clarke","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa595","article-title":"Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis","volume":"60","author":"Maccora","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23150","article-title":"Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT","volume":"23","author":"Ramanan","year":"2019","journal-title":"Health Technol Assess"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013818.pub2","article-title":"Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis","volume":"2022","author":"Renton","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.38741","article-title":"Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry","volume":"66","author":"Schmeling","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2545520","article-title":"How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study","volume":"25","author":"I\u015f\u0131k","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000206","article-title":"Advances in the treatment of polyarticular juvenile idiopathic arthritis","volume":"27","author":"Webb","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.620340","article-title":"The efficacy and safety of infliximab in refractory noninfectious uveitis: a meta-analysis of observational studies","volume":"12","author":"Xiong","year":"2021","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02795-3","article-title":"Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy","volume":"38","author":"Kreps","year":"2024","journal-title":"Eye (Lond)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/765380","article-title":"High dose infliximab in the treatment of refractory uveitis: does dose matter","volume":"2012","author":"Sukumaran","year":"2012","journal-title":"ISRN Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171006","article-title":"Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis","volume":"45","author":"Cecchin","year":"2018","journal-title":"J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12969-021-00630-1","article-title":"Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to adalimumab","volume":"19","author":"Lanz","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2081584","article-title":"The efficacy of golimumab against non-infectious uveitis: a PRISMA-compliant systematic review and meta-analysis","volume":"31","author":"Okada","year":"2023","journal-title":"Ocul Immunol Inflammation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2391985","article-title":"Intravenous golimumab in the treatment of juvenile idiopathic arthritis and its associated uveitis","volume":"33","author":"Khan","year":"2025","journal-title":"Ocul Immunol Inflammation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-013-0064-z","article-title":"Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol","volume":"28","author":"Pasut","year":"2014","journal-title":"BioDrugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100633","article-title":"Certolizumab pegol \u2013 tumor necrosis factor inhibitor for refractory uveitis","volume":"18","author":"Sharon","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","article-title":"Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry","volume":"22","author":"Armaroli","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","article-title":"Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)","volume":"75","author":"Klotsche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12969-023-00928-2","article-title":"Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment","volume":"21","author":"Dehoorne","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"B33","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-026-04460-x","article-title":"Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies","volume":"40","author":"Rees","year":"2026","journal-title":"Eye (Lond)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13075-025-03688-4","article-title":"Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology","volume":"27","author":"Burlo","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02468-1","article-title":"Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial","volume":"405","author":"Acharya","year":"2025","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in juvenile idiopathic arthritis\u2013associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial","volume":"207","author":"Horton","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.43165","article-title":"Recurrence risk in pediatric noninfectious uveitis during adalimumab tapering: an international multicenter retrospective study","volume":"77","author":"Marino","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000811","article-title":"Safety updates in novel therapeutics for pediatric rheumatic disease","volume":"33","author":"Randell","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002220","article-title":"Noninfectious uveitis in pediatric rheumatology: long-term follow-up at tertiary centers","volume":"31","author":"Akay","year":"2025","journal-title":"J Clin Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1966054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:13:41Z","timestamp":1788786821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1966054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1966054"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1966054","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1966054"}}